GeneFerm Biotechnology Co., Ltd.
1796
Rank in Stocks
#24306
GeneFerm Biotechnology Co., Ltd. specializes in the development, production,... GeneFerm Biotechnology Co., Ltd. specializes in the development, production, and global distribution of fermented health and wellness products, serving both the Taiwanese domestic market and international clients. The company's extensive product line includes a variety of microbial fermentation offerings such as different types of mushrooms, lactic acid bacteria, other bacterial strains, yeast, and algae. Furthermore, GeneFerm provides a wide array of bio-fermented ingredients, including specialized powders like nattomena, natto fermented powder, red yeast rice fermented powder, and various mycelial powders (e.g., antrodia cinnamomea, cordyceps, reishi, phellinus linteus, armillaria mellea). They also supply beta-glucan powder, fermented fruit and vegetable enzymes, as well as probiotic and peptide components. Beyond its product sales, GeneFerm offers additional services such as private label supplement manufacturing, packaging equipment, and expert microbial fermentation toll manufacturing and consulting. Established in 1988, the company maintains its headquarters in Tainan City, Taiwan.
Share Price
$0.82460461
Last synced: 2026-11-10
Market Cap
$34.19M
Change (1 day)
0.56%
Change (1 year)
-47.84%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade GeneFerm Biotechnology Co., Ltd. (1796)
Category
Healthcare
Operating Margin for GeneFerm Biotechnology Co., Ltd. (1796)
Operating Margin as of November 2026 TTM: 2.97%
According to GeneFerm Biotechnology Co., Ltd.'s latest financial reports, its current operating margin (TTM) is 2.97%. At the end of 2025 the company had an operating margin of 6.80%.
Operating Margin history for GeneFerm Biotechnology Co., Ltd. from 2019 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 2.97% | -56.32% |
| 2025 | 6.80% | -199.85% |
| 2024 | -6.81% | -135.19% |
| 2023 | 19.35% | 8.28% |
| 2022 | 17.87% | 17.95% |
| 2021 | 15.15% | 218.28% |
| 2020 | 4.76% | -166.85% |
| 2019 | -7.12% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 19.41% | -93.46% |
DE
|
|
| 19.68% | -93.37% |
DE
|
|
| 13.26% | -95.54% |
JP
|
|
| 17.08% | -94.25% |
CH
|
|
| 14.92% | -94.98% |
IL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about GeneFerm Biotechnology Co., Ltd.'s operating margin
What is GeneFerm Biotechnology Co., Ltd.'s operating margin?
GeneFerm Biotechnology Co., Ltd.'s operating margin is 2.97%, as of Nov 2026.
What was GeneFerm Biotechnology Co., Ltd.'s operating margin in 2025?
In 2025, GeneFerm Biotechnology Co., Ltd.'s operating margin was 6.80%, compared with -6.81% in 2024.
How has GeneFerm Biotechnology Co., Ltd.'s operating margin changed since 2020?
From 2020 to 2025, GeneFerm Biotechnology Co., Ltd.'s operating margin was highest in 2023 (19.35%) and lowest in 2024 (-6.81%).
How does GeneFerm Biotechnology Co., Ltd.'s operating margin compare with similar companies?
GeneFerm Biotechnology Co., Ltd.'s operating margin (2.97%) is lower than that of all 5 similar companies listed above. The highest among them is Merck KGaA, with 19.68%.